Top Markets
Coin of the day
Heat Biologics, Inc. Heat Biologics, Inc.

Heat Biologics, Inc.

HTBX
Classifica tra le azioni #24400
Heat Biologics, Inc. is an integrated biopharmaceutical company focused on... Heat Biologics, Inc. is an integrated biopharmaceutical company focused on creating immune-modulating therapies and vaccines. The firm's primary goal is to harness the immune system to fight a variety of illnesses, including both cancerous growths and infectious diseases. A cornerstone of their approach is the gp96 platform, which comprises two key components: ImPACT, an allogenic cell-based system designed to stimulate and proliferate T-cells as an immune activator, and ComPACT, a singular product engineered to achieve both antigen-driven T-cell activation and specific co-stimulation simultaneously. Their development pipeline includes several clinical-stage assets. HS-110 has finished enrolling patients for its Phase II trial targeting advanced non-small cell lung cancer, while HS-130 is currently in a Phase I clinical trial for advanced solid tumors. Furthermore, PTX-35, a novel T-cell co-stimulator agonist antibody that acts on DR3/TNFRSF25, is being evaluated in a Phase I clinical trial for diverse immunotherapy applications. The company is also advancing a COVID-19 vaccine, which is currently in the preclinical stage. Heat Biologics, Inc. has partnered with Dr. James Shapiro at the University of Alberta to develop a surrogate mouse version of PTX-35. The company was founded in 2008 and is headquartered in Morrisville, North Carolina.
Prezzo delle azioni
$2.38
Ultima sincronizzazione: 2022-05-03
Capitalizzazione di mercato
$61.07M
Variazione (1 giorno)
0.00%
Variazione (1 anno)
0.00%
Paese
US
Scambia Heat Biologics, Inc. (HTBX)

Categoria

Rapporto P/B per Heat Biologics, Inc. (HTBX)
Rapporto P/B al 2026 TTM: 0
Secondo gli ultimi rapporti finanziari e il prezzo delle azioni di Heat Biologics, Inc., il rapporto P/B attuale (TTM) è 0. Alla fine del 2026, era pari a 0.
Storico del rapporto P/B per Heat Biologics, Inc. da 2026 a 2026
Rapporto P/B alla fine di ogni anno
Anno Rapporto P/B Cambia
Non abbastanza dati per le date fornite.
Rapporto P/B per aziende simili o concorrenti
Azienda Rapporto P/B Differenza del rapporto P/B Il paese
6.3419 -
US
6.2413 -
NL
3.7087 -
US
2.5054 -
AU
- -
CH